- Home
- RDHL vs PMAX Comparison
RDHL vs PMAX Comparison
Compare RDHL & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDHL | PMAX |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Israel | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.7M |
| IPO Year | 2012 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RDHL | PMAX |
|---|---|---|
| Price | $0.55 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 99.8K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.20 |
| 52 Week High | $2.79 | $5.20 |
Technical Indicators
Market Signals| Indicator | RDHL | PMAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 36.29 |
| Support Level | N/A | $0.75 |
| Resistance Level | $0.76 | $1.38 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 2.07 | 28.59 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
About PMAX Powell Max Limited
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.